3PBIOVIAN
Antti Nieminen currently serves as Deputy CEO at 3PBIOVIAN since February 2024 and as a Board Member for Finnish bioindustries since June 2022. Since February 2003, Antti has been the CEO of Biovian, a Contract Development and Manufacturing Organization (CDMO) specializing in GMP manufacturing of biopharmaceuticals, and has also held roles as Director of Business Development and Projects and Project Manager at the same company. Additionally, Antti has been a Board Member at Hidex since June 2018 and holds a Master of Science (M.Sc.) degree in Biotechnology from the University of Turku, obtained between 1996 and 2001.
This person is not in any teams
This person is not in any offices
3PBIOVIAN
3PBIOVIAN service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, with the provision for fill and finish services for recombinant proteins and viral vectors. Leveraging a combined track record of 40 years in process development and analytical methods development, complemented by the experience in process scale-up, GMP manufacturing, and commercial supply, 3PBIOVIAN is equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.